COVID-19: India records 1,054 fresh cases, 29 more deaths

A reduction of 233 cases was recorded in the active caseload in a span of 24 hours, it added. The daily positivity rate was recorded at 0.25 per cent and the weekly positivity rate was 0.23 per cent, according to the official data.

PTI

April 10, 2022 / 10:17 IST

Representative image

With 1,054 fresh cases, India’s COVID-19 tally has climbed to 4,30,35,271, while the death toll due to the viral disease has gone up to 5,21,685 with 29 more fatalities, the Union health ministry said on Sunday.

However, the number of active cases of the infection has further declined to 11,132, according to the ministry’s data updated at 8 am. The active cases account for 0.03 per cent of the total caseload, while the national COVID-19 recovery rate remained at 98.76 per cent, the ministry said.

A reduction of 233 cases was recorded in the active caseload in a span of 24 hours, it added. The daily positivity rate was recorded at 0.25 per cent and the weekly positivity rate was 0.23 per cent, according to the ministry.

Also Read: XE COVID Variant | Here is what we know about the sub-variant of Omicron

The number of people who have recuperated from the disease has gone up to 4,25,02,454, while the case fatality rate was recorded at 1.21 per cent. The total number of Covid vaccine doses administered in the country has exceeded 185.7 crore.

India’s COVID-19 tally had crossed the 20-lakh mark on August 7, 2020, 30 lakh on August 23, 2020, 40 lakh on September 5, 2020 and 50 lakh on September 16, 2020. It went past 60 lakh on September 28, 2020, 70 lakh on October 11, 2020, 80 lakh on October 29, 2020, 90 lakh on November 20, 2020 and the one-crore mark on December 19, 2020.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show